First generation leishmaniasis vaccines: a review of field efficacy trials.

[1]  U. Nieminen,et al.  Letter: Cervical screening. , 1974, Lancet.

[2]  Responses to Montenegro antigen after immunization with killed Leishmania promastigotes. , 1978, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  M. N. Melo,et al.  A field trial of a vaccine against American dermal leishmaniasis. , 1979, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[4]  E. Javadian,et al.  Effectiveness of leishmanization in the control of cutaneous leishmaniasis. , 1983, Bulletin de la Societe de pathologie exotique et de ses filiales.

[5]  M. N. Melo,et al.  An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil. , 1985, Annals of tropical medicine and parasitology.

[6]  C. Antunes,et al.  Controlled field trials of a vaccine against New World cutaneous leishmaniasis. , 1986, International journal of epidemiology.

[7]  M. Ulrich,et al.  IMMUNOTHERAPY VERSUS CHEMOTHERAPY IN LOCALISED CUTANEOUS LEISHMANIASIS , 1987, The Lancet.

[8]  C. P. Thakur,et al.  Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. , 1992, Annals of tropical medicine and parasitology.

[9]  V. Toledo,et al.  Vaccine for prophylaxis and immunotherapy, Brazil. , 1996, Clinics in dermatology.

[10]  A. Khamesipour,et al.  Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. , 1996, Clinics in dermatology.

[11]  K. Bahar,et al.  Stepwise safety trial of a killed Leishmania vaccine in Iran. , 1996, Clinics in dermatology.

[12]  E. Javadian,et al.  The experience of leishmanization in the Islamic Republic of Iran. , 1997 .

[13]  J. Berman,et al.  Inefficacy of Allopurinol as Monotherapy for Colombian Cutaneous Leishmaniasis , 1997, Annals of Internal Medicine.

[14]  R. Armijos,et al.  Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. , 1998, The Journal of infectious diseases.

[15]  E. Zijlstra,et al.  Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. , 1998, Annals of tropical medicine and parasitology.

[16]  A. Khamesipour,et al.  Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran , 1998, The Lancet.

[17]  A. Khamesipour,et al.  A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. , 1999, Vaccine.

[18]  Gafurov Im.  Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan , 1999 .

[19]  I. Gafurov.  [Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan]. , 1999, Meditsinskaia parazitologiia i parazitarnye bolezni.

[20]  H. Ghalib,et al.  Safety and immunogenicity of an autoclaved Leishmania major vaccine. , 2009, East African medical journal.

[21]  F. Modabber,et al.  Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan , 2000, The Lancet.

[22]  J. Berman,et al.  Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[23]  A. B. Reis,et al.  A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. , 2001, Acta tropica.

[24]  E. Zijlstra,et al.  Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. , 2001, Vaccine.

[25]  A. Bryceson.  A policy for leishmaniasis with respect to the prevention and control of drug resistance , 2001, Tropical medicine & international health : TM & IH.

[26]  E. Handman.  Leishmaniasis: Current Status of Vaccine Development , 2001, Clinical Microbiology Reviews.

[27]  F. Modabber,et al.  Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial , 2002, International journal of dermatology.

[28]  V. Toledo,et al.  Vaccination of C57BL/10 mice against cutaneous Leishmaniasis using killed promastigotes of different strains and species of Leishmania. , 2002, Revista da Sociedade Brasileira de Medicina Tropical.

[29]  A. Khamesipour,et al.  The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. , 2002, Vaccine.

[30]  S. Croft,et al.  Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs. , 2003, Trends in parasitology.

[31]  O. Zerpa,et al.  Immunotherapy of american cutaneous leishmaniasis in Venezuela during the period 1990-99. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[32]  R. Armijos,et al.  Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last? , 2003, Journal of Infectious Diseases.

[33]  A. Khamesipour,et al.  Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG , 2003, Clinical and experimental immunology.

[34]  R. Haque,et al.  Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. , 2003, The American journal of tropical medicine and hygiene.

[35]  S. Croft,et al.  Leishmaniasis: new approaches to disease control , 2003, BMJ : British Medical Journal.

[36]  F. Modabber,et al.  Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[37]  W. Cevallos,et al.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. , 2004, Vaccine.

[38]  A. Khamesipour,et al.  Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. , 2005, Vaccine.

[39]  S. Sundar,et al.  Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models , 2005, Parasitology Research.

[40]  K. Dellagi,et al.  The predictive validity of naturally acquired delayed-type hypersensitivity to leishmanin in resistance to Leishmania major-associated cutaneous leishmaniasis. , 2005, The Journal of infectious diseases.

[41]  R. Coler,et al.  Second-generation vaccines against leishmaniasis. , 2005, Trends in parasitology.

[42]  F. Modabber,et al.  Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[43]  M. Ouellette,et al.  Unresponsiveness to Glucantime Treatment in Iranian Cutaneous Leishmaniasis due to Drug-Resistant Leishmania tropica Parasites , 2006, PLoS medicine.

[44]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[45]  E. Khalil,et al.  Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study , 2006, Annals of tropical paediatrics.

[46]  F. Dantas-Torres,et al.  Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. , 2006, Revista do Instituto de Medicina Tropical de Sao Paulo.

[47]  A. Khamesipour,et al.  Leishmaniasis vaccine candidates for development: a global overview. , 2006, The Indian journal of medical research.

[48]  Sassan Noazin,et al.  Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.